Q-omics provides the consensus-scored IGLV3-21 profile across patient tissues and cancer cell-line models. IGLV3-21 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGLV3-21 is differentially expressed in 8, with the highest sampling consensus in LUAD. Additionally, IGLV3-21 RNA expression shows 15,181 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, LUAD, and LSCC as cancer lineages where IGLV3-21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGLV3-21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGLV3-21 survival associations across molecular data types. IGLV3-21 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGLV3-21 RNA expression–survival associations across cancer types. High IGLV3-21 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, UCEC, LUAD and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGLV3-21 RNA expression.
This table summarizes IGLV3-21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 6. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for IGLV3-21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGLV3-21 shows lower tumor expression in COAD and higher tumor expression in LUAD, KIRC, BLCA, ESCA and HNSC. The LUAD box plot shows higher IGLV3-21 RNA expression in tumor versus normal tissue (log2 FC = +2.587, t-test p < 0.001).
This table shows molecular features associated with IGLV3-21 in patient tissues and cancer cell lines. In patient samples, IGLV3-21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
